AMEBA Amoeba SA

Edison issues report on Amoéba (ALMIB)

Edison Investment Research Limited
Edison issues report on Amoéba (ALMIB)

21-Jun-2024 / 12:36 GMT/BST
The issuer is solely responsible for the content of this announcement.

 

London, UK, 21 Juni 2024

 

Edison issues report on Amoéba (ALMIB)

to view the full report.

All reports published by Edison are available to download free of charge from its website

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

+44 (0)20 3077 5700

Connect with Edison on:

 

LinkedIn 

X  

YouTube 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1930811  21-Jun-2024 

fncls.ssp?fn=show_t_gif&application_id=1930811&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
21/06/2024

Underlying

AMEBAAmoeba SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amoeba SA

Guy Sips
  • Guy Sips
AMEBA AMOEBA SA

Amoéba Capital increase to support its industrial and commercial rollo...

We updated our model (new € 1.5 Target Price, Buy) after Amoéba announced the closure of its capital increase to support its industrial and commercial rollout. Amoeba has therefore raised a gross amount of €14m, including €9m in cash contributed by institutional and individual investors, and €5m by offsetting receivables bringing the number of shares to 68.9m. Amoéba indicated they now have sufficient financial resources to support its industrial and commercial growth and create value for its ...

07/24/25 July 24, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Exemption from obligation to destroy trial crops in France

The French regulator ANSES has granted an exemption for Amoéba's biocontrol product Axpera, allowing crop trials without the usual requirement to destroy the harvest. This exemption, which applies to both open-field and greenhouse crops affected by various diseases, supports ongoing evaluations and follows recent regulatory milestones in France and the EU. While no material commercial sales are expected yet in 2025, the move is seen as another strong endorsement of Amoéba's innovative technology...

06/25/25 June 25, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba EU approval for Axpera's active substance

Amoéba has received final approval from the European Commission for the active substance of its biocontrol product, Axpera, marking it as a low-risk substance. This milestone concludes a five-year EU validation process and positions the company for commercialisation in Europe, with marketing authorisation applications underway in nine countries and decisions expected by late 2025/early 2026. We maintain a Buy rating with € 1.8 TP.

06/18/25 June 18, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Partnership with Koppert signed

Amoéba has finalized a major five-year distribution agreement with Dutch biocontrol leader Koppert for its biofungicide Axpera, following a memorandum of understanding signed in December 2024. The deal grants Koppert exclusive rights across 18 European countries and the US, with a product launch expected in early 2026 under Koppert's brand. Production will occur at Amoéba's Chassieu site and via CDMO partners. The companies also plan to co-develop new biofungicide solutions. While financial term...

06/04/25 June 4, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Unanimously positive EU vote on active substance as biocontrol

Amoéba received unanimous positive votes from all 27 EU Member States for its active substance to be used as a low-risk biocontrol. The vote followed a positive scientific opinion from EFSA in January 2025 and now paves the way for the European Commission to formalize the approval through an implementing regulation. The vote supports Amoéba's plans to commercialize its biocontrol product Axpera, with first EU sales expected by late 2025 or 2026, as the final product is already undergoing regulat...

05/22/25 May 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch